

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**

Tumor: **Skin - Melanoma** | Stage: **IV**

Summary

Patient clinical history (23-Jan-2022)

Relevant systemic treatment history	Vemurafenib (2/2021), Ipilimumab (2022)
Other oncological history	Resection (2020)
	Previous primary tumor: Bone/Soft tissue Schwannoma (2/2019, considered active)
Relevant non-oncological history	Pancreatitis, Myocardial infarction

Patient current details (23-Jan-2022)

Unresolved toxicities grade => 2	Fatigue (2), Dizziness
Significant aberration on latest ECG	Atrial arrhythmia
Cancer-related complications	Ascites

Tumor details (23-Jan-2022)

Biopsy location	Liver
Lesion locations	CNS (active, not symptomatic), Liver, Pulmonal, Abdominal
Measurable disease (RECIST)	Yes

Laboratory results (23-Jan-2022)

Liver function	Total bilirubin		
	ASAT	(< 33 U/l)	36 U/l (no trend information available)
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	> 100 mL/min (03-Jan-2022)
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	5.5 mmol/L (no trend information available)
	Thrombocytes	(155 - 350 10 ⁹ /L)	150 10⁹/L (out of range for 2 cons. measurements, trend down)
	LDH	(< 245 U/L)	240 U/L (13-Jan-2022)

Molecular results (WGS, 28-Jan-2022)

Molecular results have reliable quality	Yes
Events with approved treatment evidence in CKB	BRAF V600E, High TML
Events with trial eligibility in ACTIN database	BRAF V600E, High TML
Additional events with experimental evidence in CKB	None
Additional events with other responsive evidence in CKB	None

Treatment Options

Trial Eligibility Summary

# Trials evaluated	1
Trials considered potentially eligible	1 (Test Trial)
# Cohorts evaluated	3
Cohorts considered potentially eligible	2 (Test Trial - Cohort B, Test Trial - Cohort C)
Open cohorts considered potentially eligible	2 (Test Trial - Cohort B, Test Trial - Cohort C)

Trial Matching Summary

Trial / Cohort	# Criteria	# Passed	# Warnings	# Failed	# Undetermined	# Not evaluated	# Non-implemented
Test Trial	3	2	0	0	0	1	0
Test Trial - Cohort A	1	0	0	1	0	0	0
Test Trial - Cohort B	0	0	0	0	0	0	0
Test Trial - Cohort C	0	0	0	0	0	0	0

Trial Matching Details

Test Trial

Evaluation **PASS**

Acronym **TEST-TRIAL**

Title **This is an ACTIN test trial**

Rule	Reference	Evaluation
I-01	Is adult	PASS
E-01	This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	NOT_EVALUATED
E-01	This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	PASS

Test Trial - Cohort A

Cohort ID **A**

Evaluation **FAIL**

Open for inclusion? **Yes**

Rule	Reference	Evaluation
I-02	Has no active CNS metastases	FAIL

Test Trial - Cohort B

Cohort ID **B**

Evaluation **PASS**

Open for inclusion? **Yes**

Test Trial - Cohort C

Cohort ID **C**

Evaluation **PASS**

Open for inclusion? **Yes**